Edward Lambert (@edwlambert) 's Twitter Profile
Edward Lambert

@edwlambert

MD, FEBU

Attending Urologic Surgeon at OLV Aalst

ID: 1096148696872435712

calendar_today14-02-2019 20:46:29

40 Tweet

135 Followers

153 Following

Edward Lambert (@edwlambert) 's Twitter Profile Photo

🔥Just out! Our paper on Retzius-sparing radical prostatectomy published in Current Oncology. ✅Superior continence results without compromising oncological outcomes when compared to the standard anterior approach! mdpi.com/1718-7729/30/3… Charles Van Praet LumenNicolaas🇻🇦

Carlo Andrea Bravi (@ca_bravi) 's Twitter Profile Photo

😎 Pleased to share the first comparative evidence on RARP performed at OLV Aalst Urology with different 🤖systems (Medtronic HUGO RAS vs. Intuitive DaVinci), published on Eur Urol Focus ➡️ 50-days free access: lnkd.in/epkVq8Rg

😎 Pleased to share the first comparative evidence on RARP performed at <a href="/AalstOlv/">OLV Aalst Urology</a> with different 🤖systems (<a href="/Medtronic/">Medtronic</a> HUGO RAS vs. <a href="/IntuitiveSurg/">Intuitive</a> DaVinci), published on <a href="/EurUrolFocus/">Eur Urol Focus</a>

➡️ 50-days free access: lnkd.in/epkVq8Rg
Edward Lambert (@edwlambert) 's Twitter Profile Photo

🔥Just out 🔥 Our European Urology Words of Wisdom Should PARP + ARTA combination therapy be the standard of care in mCRPC? authors.elsevier.com/c/1hqPf14kplvA… Morgan Roupret European Urology #prostatecancer

Louis Lenfant (@drlenfant) 's Twitter Profile Photo

🚨European Urology 💥Robot assisted vs open periprostatic artificial urinary sphincter for ♂️neurogenic SUI💥 ↘️operative times & LOS ↘️EBL & complications 🟰urinary continence 📰shorturl.at/euW25 📺 shorturl.at/ctE13 chartier-kastler e Christophe Vaessen Morgan Roupret Edward Lambert

Edward Lambert (@edwlambert) 's Twitter Profile Photo

🔥🚨Proud to share the largest series of robot-assisted vs. open periprostatic AUS for male neurogenic SUI. 🤖 = ✅ ↘️ Complications ↘️ Blood loss ↘️ Operative time ↘️ LOS 🟰 Urinary continence European Urology chartier-kastler e Christophe Vaessen Morgan Roupret Louis Lenfant authors.elsevier.com/c/1h-z814kplvA…

Koenraad van Renterghem (@koenraadvanren1) 's Twitter Profile Photo

Let's break the silence, challenge the stigma, and prioritize men's health this month and beyond. Together, we can make a difference. Laten we het zwijgen doorbreken, stigma wegwerken & de gezondheid van mannen deze maand en daarna prioriteit geven. Samen maken we het verschil💙

Let's break the silence, challenge the stigma, and prioritize men's health this month and beyond. Together, we can make a difference.

Laten we het zwijgen doorbreken, stigma wegwerken &amp; de gezondheid van mannen deze maand en daarna prioriteit geven. Samen maken we het verschil💙
Edward Lambert (@edwlambert) 's Twitter Profile Photo

Very happy and honoured to have shared our insights from OLV Aalst Urology on robot-assisted cystectomy with neobladder at this wonderfull first RARC - neobladder masterclass. Hope to see you again next year!

Very happy and honoured to have shared our insights from <a href="/AalstOlv/">OLV Aalst Urology</a> on robot-assisted cystectomy with neobladder at this wonderfull first RARC - neobladder masterclass. Hope to see you again next year!
Tom Powles (@tompowles1) 's Twitter Profile Photo

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR&gt; 50% questions unselected surgery
Pierre Blanchard, MD (@pblanchardmd) 's Twitter Profile Photo

KN905 Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25 ✅Improved PFS & OS ✅High path CR rates (57%) ✅No delay in surgery ✅Expected toxicity in this frail population New SOC

KN905

Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25

✅Improved PFS &amp; OS
✅High path CR rates (57%)
✅No delay in surgery
✅Expected toxicity in this frail population

New SOC
Edward Lambert (@edwlambert) 's Twitter Profile Photo

pCR rate of 57% after NA EV+P in Cis ineligble BCa patients. How will we select those who can preserve their bladder? Exciting data presented by christof at #ESMO25 #bladdercancer

pCR rate of 57% after NA EV+P in Cis ineligble BCa patients. How will we select those who can preserve their bladder?
Exciting data presented by <a href="/cvulsteke/">christof</a> at #ESMO25 #bladdercancer
Edward Lambert (@edwlambert) 's Twitter Profile Photo

🛜🥇🤖First teleproctoring case in Europe: Robot-assisted radical prostatectomy tele-surgery with two sugeons 600 kms apart as a live-case for the German Society for Robot-Assisted Urology #DRUS congress 🇩🇪. geert de naeyer Alex Mottrie MicroPort #Toumai youtube.com/watch?v=XfhQRd…